Also today, maintenance chemotherapy is the first treatment advancement for rhabdomyosarcoma in 30 years for younger patients, a tumor analysis suggests testing all MSI-high patients for Lynch Syndrome, and for metastatic castration-resistant prostate cancer, black men have a stronger response to abiraterone (Zytinga).
Listen to the MDedge Daily News podcast for all the details on today’s top news.